In the last 12 months, insiders at Q/C TECHNOLOGIES, INC. ($QCLS) filed 19 transactions with the SEC: 2 open-market purchases totaling $0 and 0 sales totaling $0. Net insider sentiment: neutral.
Q/C TECHNOLOGIES, INC. operates in the In vitro & in vivo diagnostic substances industry (Life sciences sector).
Most Active Insiders
- RHODES IAN (Interim CFO) — 1 transaction totaling $0
- Friscia Stephen (Director) — 2 transactions totaling $0
- Bernstein Bruce (Director) — 1 transaction totaling $0
- Glass Mitchell (Director, Chief Medical Off.) — 2 transactions totaling $0
- Glass Mitchell (President, CMO) — 1 transaction totaling $0
View all SEC Filings for Q/C TECHNOLOGIES, INC. (QCLS).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 16, 2026 | Voss Chelsea Sierra | Director | A | Common stock | 212500 | $0.00 | 274,702.0000 | 4,166,760 | 341.63% | 5.10% |
| Jan. 16, 2026 | Voss Chelsea Sierra | Director | A | Employee Stock Option (Right to Buy) | 212500 | $0.00 | 212,500.0000 | 4,166,760 | 9999.99% | 5.10% |
| Jan. 16, 2026 | Voss Chelsea Sierra | Director | A | Common stock | 25000 | $0.00 | 299,702.0000 | 4,166,760 | 9.10% | 0.60% |
| Nov. 14, 2025 | PharmaCyte Biotech, Inc. | TenPercentOwner | P | Warrants | 889865 | $0.00 | 889,865.0000 | 10,132,619 | 9999.99% | 8.78% |
| Sept. 4, 2025 | PharmaCyte Biotech, Inc. | TenPercentOwner | P | Series H Convertible Preferred Stock | 889865 | $0.00 | 889,865.0000 | 10,132,619 | 9999.99% | 8.78% |
| Nov. 14, 2025 | Glass Mitchell | Director, Chief Medical Off. | A | Common stock | 11420 | $0.00 | 12,500.0000 | 10,132,619 | 1057.41% | 0.11% |
| Nov. 14, 2025 | White Billy Joe | Director | A | Common stock | 22839 | $0.00 | 25,024.0000 | 10,132,619 | 1045.26% | 0.23% |
| Nov. 14, 2025 | Friscia Stephen | Director | A | Common stock | 22839 | $0.00 | 25,000.0000 | 10,132,619 | 1056.87% | 0.23% |
| Nov. 14, 2025 | Silverman Joshua | Executive Chairman | A | Common stock | 91356 | $0.00 | 100,029.0000 | 10,132,619 | 1053.34% | 0.90% |
| Nov. 14, 2025 | Bernstein Bruce | Director | A | Common stock | 25000 | $0.00 | 25,000.0000 | 10,132,619 | 9999.99% | 0.25% |
| Nov. 14, 2025 | RAUCH GARY M | Other | A | Common stock | 11420 | $0.00 | 12,500.0000 | 10,132,619 | 1057.41% | 0.11% |
| Oct. 3, 2025 | Silverman Joshua | Executive Chairman | A | Common stock | 8644 | $0.00 | 8,673.0000 | 10,132,619 | 9999.99% | 0.09% |
| Oct. 3, 2025 | RAUCH GARY M | Other | A | Common stock | 1080 | $0.00 | 1,080.0000 | 10,132,619 | 9999.99% | 0.01% |
| Oct. 3, 2025 | White Billy Joe | Director | A | Common stock | 2161 | $0.00 | 2,185.0000 | 10,132,619 | 9004.17% | 0.02% |
| Oct. 3, 2025 | Glass Mitchell | Director, Chief Medical Off. | A | Common stock | 1080 | $0.00 | 1,080.0000 | 10,132,619 | 9999.99% | 0.01% |
| Oct. 3, 2025 | Friscia Stephen | Director | A | Common stock | 2161 | $0.00 | 2,161.0000 | 10,132,619 | 9999.99% | 0.02% |
| April 17, 2025 | Glass Mitchell | President, CMO | A | Employee Stock Option (Right to Buy) | 125000 | $0.00 | 125,000.0000 | 10,132,619 | 9999.99% | 1.23% |
| April 17, 2025 | RAUCH GARY M | Other | A | Employee Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 10,132,619 | 9999.99% | 0.74% |
| April 17, 2025 | RHODES IAN | Interim CFO | A | Employee Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 10,132,619 | 9999.99% | 0.25% |